Diclofenac epolamine is effective in the treatment of acute migraine attacks. A randomized, crossover, double blind, placebo-controlled, clinical study

L. Vécsei, G. Gallacchi, I. Sági, J. Semjén, J. Tajti, D. Szok, M. Müller, P. Vadass, M. Kerékgyártó

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Hydrosoluble diclofenac epolamine (DHEP) represents an interesting approach to acute migraine attacks, where gastrointestinal motility and drug absorption are often reduced. Its efficacy was investigated in a randomized, crossover, double-blind trial on 155 patients who treated four consecutive mild-to-moderate migraine attacks, either with DHEP (65-mg sachet) or placebo. If pain was not relieved within 1 h, a second dose was given. The total number of treated attacks was 481. A pain-free condition was achieved within 2 h in 45.8% and 25.1% of attacks treated, respectively, with DHEP or placebo (P < 0.0001), with a therapeutic gain of 20.7%. Time to attack resolution, light and noise sensitivity and impact on working ability were significantly reduced by DHEP compared with placebo. Moreover, significantly fewer patients required a second drug dose or a rescue medication when treated with DHEP than with placebo. No adverse reaction was recorded. In conclusion, DHEP was effective and safe for pain relief in patients with an acute mild-to-moderate migraine attack.

Original languageEnglish
Pages (from-to)29-34
Number of pages6
JournalCephalalgia
Volume27
Issue number1
DOIs
Publication statusPublished - Jan 1 2007

Keywords

  • Diclofenac
  • Epolamine
  • Migraine
  • Randomized clinical trial

ASJC Scopus subject areas

  • Clinical Neurology

Fingerprint Dive into the research topics of 'Diclofenac epolamine is effective in the treatment of acute migraine attacks. A randomized, crossover, double blind, placebo-controlled, clinical study'. Together they form a unique fingerprint.

  • Cite this